

DEZAWA MUSECELLS®

THE FUTURE OF STEM CELL TECHNOLOGY



Dezawa Musecells® are a unique subpopulation of stem cells. Being stress resilient and pluripotent-like, with capacity for both allogeneic and autologous use, and extremely low risk of tumorigenicity, Dezawa MuseCells® can help regenerative medicine reach its full potential, safely and effectively.

	Dezawa MuseCells®	Traditional MSCs
DIFFERENTIABLE CELL TYPES	Most cell types in the body	Osteocytes, chondrocytes, adipocytes
DIFFERENTIATION ABILITY IN VIVO	Yes	Very low rate, if any
TUMORIGENICITY	None	None
IMMUNE REJECTION DUE TO USE OF DONOR CELLS	None	Lesser extent
IMMUNOSUPPRESSANT TREATMENT	Not necessary	Case-by-case
MOST EFFECTIVE METHOD FOR DELIVERY TO TARGET ORGAN	Intravenous infusion	Local injection
DISTRIBUTION IN THE BODY AFTER INTRAVENOUS INJECTION	Target (damaged) organ	
DELIVERY RATE TO TARGET ORGAN AFTER INTRAVENOUS INJECTION	~15%	Less than 1%, if any
MAIN FUNCTIONS AFTER HOMING TO TARGET ORGAN:		
• REPLACEMENT OF DAMAGED CELLS BY DIFFERENTIATION	Yes	No
• ANGIOGENESIS	Yes	No
• VASCULAR PROTECTION	Yes	Yes
• ANTI-INFLAMMATORY EFFECT	Yes	Yes
• ANTI-FIBROTIC EFFECT	Yes	Yes
• TISSUE PROTECTIVE EFFECT	Yes	Yes
SURVIVAL IN TARGET ORGAN	Longer than several years	No
NECESSITY FOR GENE MANIPULATION	No	No

*Traditional MSCs may cause stronger immune responses—leading to more rejection, swelling, and inflammation. In up to 15% of patients, they also trigger antibodies, especially after multiple treatments¹⁻³. According to studies, Dezawa MuseCells® decrease these occurrences because they survive longer in tissues, calm inflammation more effectively, and usually don't require donor matching. **Learn more at musecellinnovations.com/research-hub***

¹PMID: 28894792 ²PMID: 28894792 ³PMID: 34279481

Claims are based on published studies of Dezawa MuseCells® produced using the licensed intellectual property and exact methodologies of MuseCell Innovations®. Only Dezawa MuseCells® originating from MCI's manufacturing ecosystem and distributed through MCI-designated, licensed partners have the safety and clinical characteristics reported in the research.